Getagraph.com logo
S&P 500
(1.02%) 5 099.96 points
Dow Jones
(0.40%) 38 240 points
Nasdaq
(2.03%) 15 928 points
Oil
(0.11%) $83.66
Gas
(-1.16%) $1.619
Gold
(0.30%) $2 349.60
Silver
(-0.43%) $27.52
Platinum
(0.42%) $924.40
USD/EUR
(0.32%) $0.935
USD/NOK
(0.67%) $11.02
USD/GBP
(0.13%) $0.800
USD/RUB
(-0.07%) $92.11

Sanntidsoppdatering for Blueprint Medicines Corp [BPMC]

Børs: NASDAQ Sektor: Healthcare Industri: Biotechnology
Upcoming Earnings Alert

4 days till quarter result
(bmo 2024-05-02)

Expected move: +/- 10.87%

BUY
72.50%
return 13.40%
SELL
52.50%
return -7.22%
Sist oppdatert26 apr 2024 @ 22:00
25% discount on Stockinvest.us - Use code: Podcast

2.50% $ 93.00

KJøP 2711 min ago

@ $93.66

Utstedt: 26 apr 2024 @ 20:20

Avkastning: -0.70%

Forrige signal: apr 25 - 18:08

Forrige signal: Selg

Avkastning: 3.76 %

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 22:00):
Our systems believe the stock currently is undervalued by 0.02% compare to its pairs and should correct upwards.

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally...

Stats
Dagens volum 710 386
Gjennomsnittsvolum 805 482
Markedsverdi 5.69B
EPS $0 ( 2024-02-15 )
Neste inntjeningsdato ( $-1.640 ) 2024-05-02
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -11.11
ATR14 $4.51 (4.85%)
Insider Trading
Date Person Action Amount type
2024-03-28 Landsittel Michael Buy 5 000 Common Stock
2024-03-28 Landsittel Michael Sell 5 000 Common Stock
2024-03-28 Landsittel Michael Sell 5 000 Stock Option (Right to Buy)
2024-03-07 Albers Jeffrey W. Sell 11 033 Common Stock
2024-03-20 Albers Jeffrey W. Buy 10 000 Common Stock
INSIDER POWER
36.49
Last 100 transactions
Buy: 596 437 | Sell: 283 237
Korrelasjon (AI algo v.1.1b): Undervalued: 0.02% $92.93 paired level. (Algoen sporer endringene til de mest korrelerte aksjene i sanntid og gir umiddelbar oppdatering)

Volum Korrelasjon

Lang: -0.72 (moderate negative)
Kort: -0.94 (very strong negative)
Signal:(49) Neutral

Blueprint Medicines Corp Korrelasjon

10 Mest positive korrelasjoner
ACBA0.958
MANH0.953
PUCK0.951
VIRI0.949
GXII0.947
AEAC0.946
ESLT0.946
RAM0.946
IVCB0.945
SKYW0.945
10 Mest negative korrelasjoner
PEAR-0.951
VORB-0.949
INFN-0.934
MKTX-0.931
BHTG-0.928
FEMY-0.927
IVAC-0.926
EDUC-0.926
TRIT-0.925
OBNK-0.924

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Blueprint Medicines Corp Korrelasjon - Valuta/Råvare

The country flag 0.86
( strong )
The country flag 0.90
( very strong )
The country flag 0.00
( neutral )
The country flag 0.88
( strong )
The country flag 0.17
( neutral )
The country flag -0.79
( moderate negative )

Blueprint Medicines Corp Økonomi

Annual 2023
Omsetning: $249.38M
Bruttogevinst: $224.92M (90.19 %)
EPS: $-8.37
FY 2023
Omsetning: $249.38M
Bruttogevinst: $224.92M (90.19 %)
EPS: $-8.37
FY 2022
Omsetning: $204.04M
Bruttogevinst: $186.22M (91.27 %)
EPS: $-9.35
FY 2021
Omsetning: $180.08M
Bruttogevinst: $162.15M (90.04 %)
EPS: $-11.81

Financial Reports:

No articles found.

Blueprint Medicines Corp

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Om Live Signaler

Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.

Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.